NCT07209059View on ClinicalTrials.gov

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Hodgkin LymphomaHodgkin DiseaseAdvanced Hodgkin Lymphoma
Interventions
DRUG

Nivolumab

Monoclonal antibody targeting PD-1; administered in combination regimens

OTHER

N-EACOPD-14

14-day regimen. Combination of Nivolumab with Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, and Dacarbazine; given for 2 cycles as initial therapy.

OTHER

N-AVD

Combination of Nivolumab with Doxorubicin, Vinblastine, and Dacarbazine; used as de-escalated therapy after negative interim PET (2 cycles).

Trial Locations (1)

125167

RECRUITING

National Medical Research Center for Hematology, Moscow

All Listed Sponsors
lead

National Research Center for Hematology, Russia

NETWORK

NCT07209059 - PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter